Tecan and Technoclone; a collaboration for the University Children’s Hospital in Zurich

Application specialists from Tecan have teamed up with Technoclone GmbH, Vienna, and the University Children’s Hospital in Zurich to validate the TECHNOTHROMBIN® thrombin generation assay (TGA) for Tecan’s Infinite® M200 multimode microplate reader.

Dr Oliver Speer, head of the Experimental Hematology and Erythrocyte Laboratory at the hospital, explained: “We installed the Infinite reader in our laboratory to standardize all of our photometric assays using just a single platform. Once we had completed the transfer of our existing assays to the Infinite, we realized that the flexibility and sensitivity of the instrument would allow us to supersede some of these assays with more efficient or sensitive methods, so became interested in the TECHNOTHROMBIN TGA.”

“Representatives from Tecan and Technoclone came to the hospital to assist with development and validation of this assay on the Infinite reader, enabling us to very quickly complete our validation study. The collaboration between the two companies was perfect for us, and we are still in regular contact with Tecan for technical assistance. The support we have received has been excellent, and Tecan has even developed the software specifically for our needs.”

To find out more on Tecan’s Infinite 200 series microplate readers, visit www.tecan.com/infinite200 

For more information about Tecan, please contact:

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2008, Tecan generated sales of CHF 396 million (USD 366.7 million; EUR 250.7 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).